Evaxion A/S(EVAX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,413 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
EVAX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Evaxion A/S (EVAX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EVAX at 32.7/100 on a 32-signal composite quality model, placing it at rank #2,413 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), Evaxion A/S reports quarterly revenue of $7.5M, net income of $-7.7M. Top institutional holders of EVAX by reported 13-F value include Merck, Ikarian Capital, Rathbones Group PLC, based on the most recent SEC filings. EVAX trades on the Nasdaq exchange and files with the SEC under CIK 1828253. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EVAX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Evaxion A/S directly from SEC EDGAR.
Revenue
FY 2025
$7.5M
Net Income
FY 2025
$-7.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+125.1% YoYTotal Assets
+127.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $7.5M +125.1% | $3.3M +4480.8% | $73.0K | $0.00 | — | — |
| Total Assets | $28.4M +127.5% | $12.5M -3.1% | $12.9M -41.5% | $22.0M -45.2% | $40.2M +235.7% | $12.0M |
Get alerted when EVAX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Evaxion A/S including:
Top Institutional Holders of EVAX
Merck & Co., Inc.
$3.8M1,214,126 shIkarian Capital, LLC
$231.6K74,698 shRathbones Group PLC
$141.7K45,723 shCITADEL ADVISORS LLC
$113.4K36,584 shRENAISSANCE TECHNOLOGIES LLC
$104.8K33,800 shAnnis Gardner Whiting Capital Advisors, LLC
$93.0K30,000 shJ. Safra Sarasin Holding AG
$71.0K22,896 shRHUMBLINE ADVISERS
$67.7K21,849 shJANE STREET GROUP, LLC
$63.8K20,581 shBOOTHBAY FUND MANAGEMENT, LLC
$57.1K18,426 sh
| Fund | Value | Shares |
|---|---|---|
| Merck & Co., Inc. | $3.8M | 1,214,126 |
| Ikarian Capital, LLC | $231.6K | 74,698 |
| Rathbones Group PLC | $141.7K | 45,723 |
| CITADEL ADVISORS LLC | $113.4K | 36,584 |
| RENAISSANCE TECHNOLOGIES LLC | $104.8K | 33,800 |
| Annis Gardner Whiting Capital Advisors, LLC | $93.0K | 30,000 |
| J. Safra Sarasin Holding AG | $71.0K | 22,896 |
| RHUMBLINE ADVISERS | $67.7K | 21,849 |
| JANE STREET GROUP, LLC | $63.8K | 20,581 |
| BOOTHBAY FUND MANAGEMENT, LLC | $57.1K | 18,426 |
More Healthcare Companies
View all Healthcare →Put EVAX on your watchlist
Track score changes the day Evaxion A/S files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is EVAX a good stock to buy?
13F Pro's AI-powered analysis of Evaxion A/S (EVAX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EVAX are available on the EVAX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. EVAX is classified as a small company.
Which hedge funds own EVAX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EVAX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Evaxion A/S's investment landscape.